AnGes assessing Vical's pandemic vaccine for Japan
This article was originally published in Scrip
Executive Summary
The Japanese bioventure AnGes MG has signed a non-binding letter of intent with Vical under which it will discuss terms for a possible licence to the US firm's H5N1 DNA vaccines.